Do tocolytic agents stop preterm labor? A critical and comprehensive review of efficacy and safety

doi:10.1016/0002-9378(93)90376-T

American Journal of Obstetrics and Gynecology

Volume 168, Issue 4, April 1993, Pages 1247-1259

https://doi.org/10.1016/0002-9378(93)90376-T Get rights and content

Objective: Our aim was to determine the efficacy and safety of tocolytic agents currently used to treat premature labor.

Study Design: We carried out a comprehensive review of tocolytic agents in the treatment of premature labor. Three hundred twenty-eight studies published between 1933 and 1992 were analyzed.

Results: An analysis of randomized, placebo-controlled, clinical trials showed that magnesium sulfate is not better than placebo in the treatment of premature labor. R-Adrenergic receptor agonists effectively stop premature labor for only 24 to 48 hours. Calcium channel blockers and oxytocin antagonists inhibit uterine contractions, but their role in stopping labor is undefined. Prostaglandin inhibitors appear to be effective in treating premature labor and have few adverse side effects.

Conclusions: The only tocolytic drugs that might be effective are the prostaglandin inhibitors. Tocolytic agents should be used only between 24 and 32 completed weeks of gestation. Magnesium sulfate should not be used to treat premature labor. Oxytocin antagonists should be used only in experimental clinical trials. Calcium channel blockers and p-adrenergic receptor agonists inhibit uterine contractions but do not prolong gestation for longer than 48 hours.

References (49)

SN Caritis et al.
Pharmacologic inhibition of preterm labor
Am J Obstet Gynecol
(1979)
FJ Zlatnik
The applicability of labor inhibition to the problem of prematurity
Am J Obstet Gynecol
(1972)
I Ingemarsson
Effect of terbutaline on premature labor
Am J Obstet Gynecol
(1976)
AI Csapo et al.
Arrest of premature labor by isoxsuprine
Am J Obstet Gynecol
(1977)
NH Lauersen et al.
Inhibition of premature labor: a multicenter comparison of ritodrine and ethanol
Am J Obstet Gynecol
(1977)
LL Penney et al.
Estimation of success in treatment of premature labor: applicability of prolongation index in a double-blind, controlled, randomized trial
Am J Obstet Gynecol
(1980)
KJ Leveno et al.
Single-centre randomised trial of ritodrine hydrochloride for preterm labour
Lancet
(1986)
CP Weiner et al.
The therapeutic efficacy and cost-effectiveness of aggressive tocolysis for premature labor associated with premature rupture of the membranes
Am J Obstet Gynecol
(1988)
CM Steer et al.
A comparison of magnesium sulfate and alcohol for the prevention of premature labor
Am J Obstet Gynecol
(1977)
SM Cox et al.
Randomized investigation of magnesium sulfate for prevention of preterm birth
Am J Obstet Gynecol
(1990)

DI Hollander et al.

Magnesium sulfate and ritodrine hydrochloride: a randomized comparison

Am J Obstet Gynecol

(1987)

JR Niebyl et al.

The inhibition of premature labor with indomethacin

Am J Obstet Gynecol

(1980)

RB Lewis et al.

Influence of acetylsalicylic acid, an inhibitor of prostaglandin synthesis, on the duration of human gestation and labour

Lancet

(1973)

O Gamissans et al.

A study of indomethacin combined with ritodrine in threatened preterm labor

Fur J Obstet Gynecol Reprod Biol

(1978)

Z Katz et al.

Treatment of premature labor contractions with combined ritodrine and indomethacin

Int J Gynaecol Obstet

(1983)

R Besinger et al.

Randomized comparative trial of indomethacin and ritodrine for the long-term treatment of preterm labor

Am J Obstet Gynecol

(1991)

JE Ferguson et al.

A comparison of tocolysis with nifedipine or ritodrine: analysis of efficacy and maternal, fetal, and neonatal outcome

Am J Obstet Gynecol

(1990)

O Castren et al.

Treatment of imminent premature labour

Acta Obstet Gynecol Scand

(1975)

M Wynn et al.

The prevention of preterm birth. London: Foundation for Education and Research in ChildBearing

(1977)

M O'Driscoll

Discussion

A Wesselius-De Casparis et al.

Results of double-blind, multicentre study with ritodrine in premature labour

BMJ

(1971)

GS Adam

Isoxsuprine and premature labour

Aust N Z J Obstet Gynaecol

(1966)

R Das

Isoxsuprine in premature labour

J Obstet Gynaecol India

(1969)

R Sivasamboo

Premature labour

Cited by (232)

Endocrine Diseases of Pregnancy
2019, Yen & Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management: Eighth Edition
Physiological and endocrine adaptations occur in the mother in response to the demands of pregnancy. These demands include support of the fetus (volume support, nutritional and oxygen supply, and clearance of fetal waste), protection of the fetus (from starvation, drugs, toxins), preparation of the uterus for labor, and protection of the mother from potential cardiovascular injury at delivery. The presence of a preexisting endocrine disorder is likely to affect the ability of the mother to adapt to the demands of pregnancy and, as a result, may influence fetal growth and development. Drugs used to treat such disorders may also affect perinatal outcome. The most common preexisting endocrine disorders that can complicate pregnancy are diabetes mellitus, thyroid dysfunction, and obesity. Less common preexisting maternal endocrine disorders include pituitary tumors, diabetes insipidus, and hyperparathyroidism.
The physiological and endocrine adaptations that characterize pregnancy can also lead to the development of pregnancy-specific diseases in previously healthy women, the most common of which are gestational diabetes and disorders of the endocrine and sympathetic nervous systems associated with preeclampsia and preterm labor. This chapter is designed to review in detail the underlying pathophysiology of these pregnancy-specific diseases, as well as the effects of pregnancy on preexisting endocrine disorders. A better understanding of these conditions will improve the ability of clinicians to optimize maternal and perinatal outcome in such pregnancies.
Preterm Intraventricular Hemorrhage/Posthemorrhagic Hydrocephalus
2018, Volpe's Neurology of the Newborn
Germinal matrix hemorrhage–intraventricular hemorrhage (GMH-IVH) is the most common variety of neonatal intracranial hemorrhage and is characteristic of the premature infant. This form of brain injury affects around 25% of all very low birthweight (<1500 g) premature infants, resulting in an increased risk for neurodevelopmental disability. Its occurrence can lead to impact on subsequent brain development because of destruction of the immature germinal cerebral region resulting in loss of progenitor cells, acceleration of white matter injury via pressure and oxidative stress, and direct parenchymal injury. Finally, hydrocephalus can complicate IVH, resulting in a further increased risk of neurodevelopmental disability. In this chapter, the neuropathology, pathogenesis, clinical features, diagnosis, prognosis, and management of IVH, and its complications will be reviewed. The prominent position of this lesion in neonatal medicine has been accompanied by a large increase in work from several disciplines. This chapter attempts to integrate this information in a meaningful way without oversimplifying a clearly complex problem.
Magnesium Sulfate: Another Cause of a Solute Diuresis
2017, American Journal of Kidney Diseases
In pregnant women, magnesium sulfate infusions are a treatment commonly used for preeclampsia and as a tocolytic agent. In this case report, a 33-year-old woman at 26 weeks of gestation received intravenous magnesium sulfate in Ringer’s lactate solution and corticosteroids for preterm uterine contractions without preeclampsia. She developed polyuria of more than 18 L in 48 hours, with urine chemistries documenting that magnesium sulfate contributed 30% of the solute in this massive isosthenuric diuresis. Therefore, magnesium sulfate should be added to the common solutes, glucose, sodium chloride, urea, and mannitol, as a cause of solute diureses.
Parameters extraction and monitoring in uterine EMG signals. Detection of preterm deliveries
2013, IRBM
Citation Excerpt :
The socio-economic consequences of these prematurity are important [2]. Indeed, some days more in utero can improve the maturation of the fetus and hence its viability at birth [3]. For this, we need a reliable method for the early detection and prevention of preterm birth threats.
The aim of this paper is to classify between labor contractions and pregnancy contractions. Various types of parameters have been extracted from the electrohysterogram (EHG), mainly from the original EHG or from different frequency bands. They have been computed from different signal databases obtained with different recording protocols. The results of these studies are sometime controversial. The aim of this paper is to compute 17 parameters selected from the literature on the same signal database, either on the original EHG or after wavelet packet decomposition, and then to compare their power to discriminate between contractions recorded during pregnancy and labor. We thus obtain a selection of parameters that allow the best discrimination between pregnancy and labor contractions, when computed on the same signals, either on the original EHG or on selected frequency bands.
Endocrine Diseases of Pregnancy
2013, Yen and Jaffe's Reproductive Endocrinology: Seventh Edition
Serum amyloid A upsurge precedes standard biomarkers of hepatotoxicity in ritodrine-injected mice
2013, Toxicology
The tocolytic agent ritodrine acts on the β2-adrenoceptor and is an effective treatment option for preterm labor. However, several adverse effects of ritodrine therapy, including liver damage, have been noted. To elucidate the underlying mechanisms of ritodrine-induced adverse effects, development of sensitive biomarkers of these adverse events is necessary. Here, we report the development and analysis of an animal model of ritodrine-induced liver damage. Female mice received daily ritodrine injections for 2 weeks; liver samples were then collected and subjected to DNA microarray analysis. Ritodrine significantly altered the expression of genes related to steroid and lipid metabolism, as well as the metabolism of ritodrine itself. Importantly, expression of the acute-phase reactant serum amyloid A (SAA) significantly increased after ritodrine injection, with values indicating the largest fold-change. This large increase in blood SAA levels serves as a more sensitive biomarker than conventional liver enzymes, such as aspartate aminotransferase and alanine aminotransferase. The increase in SAA expression is specific to ritodrine-induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or metformin. Our in vitro studies showed that cyclic adenosine 3′,5′-monophosphate (cAMP) accumulation was not a primary cause of the ritodrine-induced SAA increase. Instead, SAA expression was enhanced by indirect phosphorylation of the signal transducer and activator of transcription-3 (STAT3) mediated by interleukin-6. Therefore, our study provides a method for sensitive and early detection of hepatic injury, and may thus help preclude serious liver damage due to ritodrine use in preterm labor.

View all citing articles on Scopus

: Panel presentation, presented by invitation at the Eleventh Annual Meeting of the American Gynecological and Obstetrical Society, Hot Springs, Virginia, September 10-12, 1992.

View full text